Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2714777 | 0.84 | MMP1 (0.34) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL7425654 | 0.83 | TSHR (0.35) | MMP1MMP2MMP3TSHR | |
| SCHEMBL5859731 | 0.82 | LAP3 (0.34) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL16537885 | 0.81 | MMP1 (0.40) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL8376607 | 0.79 | MGAM (0.39) | MMP1MMP2MMP3TSHR | |
| SCHEMBL5665071 | 0.79 | LAP3 (0.33) | MMP1MMP2MMP3LAP3METAP1 | |
| SCHEMBL776263 | 0.79 | LAP3 (0.36) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL11785925 | 0.78 | CYP2D6 (0.31) | — | |
| SCHEMBL8910013 | 0.77 | LAP3 (0.33) | LAP3METAP1 | |
| SCHEMBL11745106 | 0.77 | LAP3 (0.34) | MMP1MMP2MMP3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596709-B1 | For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea | LES LABORATOIRES SERVIER (FR) | 2003-07-22 | — | — | US | disclosed |
| US-6518258-B1 | 6-sulphamoyl -3-quinolyphosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2003-02-11 | — | — | US | disclosed |
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-6420386-B1 | SPINAL TRAUMATISM, EPILEPSY, CHRONIC NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, SCHIZOPHRENIA, LATERAL AMYOTROPHIC SCLEROSIS OR HUNTINGTON'S CHOREA. | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | CA6, P2RY6, FPR3 | MMP1 3475/4885MMP2 4279/4885MMP3 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.